MD-MAGBIO-GENOMICS
MagBio Genomics, Inc., a global company focused on magnetic bead-based products for molecular diagnostics and liquid biopsy genomic research, announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE Mark approval and global launch of its MagXtract Collection Tube. Used for sample collection and processing, the MagXtract Collection Tube is the first guanidine-free molecular transport medium, FDA-cleared device available in the U.S. for COVID-19 testing. In Europe the MagXtract Collection Tube is versatile, available for testing both COVID-19 and Influenza. It is also validated for bacterial and fungal sample collection and stabilization in research studies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005273/en/
The new MagXtract Collection Tube from MagBio Genomics offers improved safety, stability and cost-effectiveness for sample collection and processing. Now available in the U.S. for COVID-19 testing and Europe for both COVID-19 and Influenza. MagXtract is the first FDA-cleared guanidine-free molecular transport medium that offers direct lysis and room temperature stability of RNA. The FDA has advised laboratory staff at COVID-19 sample processing facilities to avoid collection devices that use guanidine-based mediums because when cleaned with bleach, it creates cyanide gas that is highly toxic and can also be fatal. (Photo: Business Wire)
“Accurate detection of pathogens by molecular assays depends on proper collection and stabilization of samples. Poor sample stabilization results in nucleic acid degradation and overgrowth of some micro-organisms, which may lead to patient misdiagnosis,” said Hyacinth K. Ntchobo, Ph.D., CEO, MagBio Genomics. “The MagXtract Collection Tube addresses these issues by providing cost-effective room temperature sample transportation and nucleic acid stabilization over prolonged time, providing clinical laboratories with high-quality samples for accurate molecular detection of pathogens.”
With the launch of the MagXtract Collection Tube, MagBio offers improved safety, stability and cost-effective sample collection and processing to the worldwide market:
- Safety during disinfection: A guanidine-free, proprietary medium makes it safe for use in clinical settings by eliminating the risk of creating cyanide gas during cleaning, which is highly toxic and can be fatal. The FDA issued a letter to laboratory staff at COVID-19 sample processing facilities to avoid collection devices that use guanidine.
- Sample Handling and Processing Safety: The medium directly lyses cells during transport and inactivates pathogens, eliminating the need for containment use.
- Stability: Ambient temperature stability of RNA samples for up to eight days eliminates the need for cold storage/shipping.
- Efficiency and cost-effectiveness: There is no need to use a lysis buffer because the transport medium also acts as a lysis buffer, reducing costs in nucleic acid extraction workflow.
To learn more about the MagXtract Collection Tube or to request a sample pack, visit www.magbiogenomics.com.
About MagBio Genomics, Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation, including biomarkers as tools for molecular diagnostics and liquid biopsy genomic research. The current focus encompasses products that cover complete sample preparation including safeguarding integrity of bio-samples, efficient isolation of nucleic acids and circulating biomarkers to target enrichment from biological samples. Our products are applied to human genetic research, including molecular diagnostics, cancer genomic studies and noninvasive prenatal testing. “We simply make NGS better.” For more information, visit www.magbiogenomics.com and follow the company on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005273/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 16:13:00 CET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
Rimini Street Announces Additional Stock Repurchase Transactions1.12.2025 15:00:00 CET | Press release
Company will share its vision, strategy, sales and execution model, financial model and guidance at its Investor Day event on December 3, 2025 Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201195169/en/ Rimini Street Announces Additional Stock Repurchase Transactions Share Repurchases The Company repurchased a total of 975,000 shares of common stock to date in the fourth fiscal quarter of 2025, for approximately $3.8 million with an average per share purchase price of $3.92, reducing outstanding shares by approximately 1.1%1. The Company has now completed and announced $13.3 million in common stock repurchases under its $50 million Common Stock Repurchase Plan that was app
MVNO Europe - Europe's Competitiveness Depends on a Truly Open Telecoms Market, Not on Increased Concentration That Benefits a Handful of Mobile Operators1.12.2025 14:37:00 CET | Press release
This is the warning that MVNO Europe – through its President Jacques Bonifay – has issued to the European Commission in an open letter to Ursula von der Leyen and Vice-President Henna Virkkunen. As discussions on the Digital Networks Act (DNA) enter their decisive phase, the association, which brings together alternative mobile operators in Europe, points out that the EU's digital ambition can only be achieved if competition remains a structuring principle, not an adjustment variable. While some players are calling for "necessary" consolidation in the sector, MVNO Europe warns against a simplistic and economically dangerous vision. "Reducing the number of operators has never guaranteed innovation, access for European industries, or fair conditions for new digital services. On the contrary, the historical driver of European competitiveness has always been the diversity of players, models, technologies and services," says Jacques Bonifay, President of MVNO Europe and CEO of Transatel. Re
IonQ and CCRM Announce Strategic Quantum-Biotech Collaboration to Accelerate Development of Advanced Therapeutics1.12.2025 13:30:00 CET | Press release
IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201706303/en/ IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network. With more than 100,000 square feet of good manufacturing practice (GMP) facilities, 300+ scientific staff and a global network of academic and industry partners, CCRM is one of t
Ares Management Introduces Marq to Further Unify its Global Logistics Platform Within its Real Estate Business1.12.2025 12:00:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it is consolidating its global logistics real estate platforms under a single brand, Marq Logistics (“Marq”). The newly launched brand, Marq, will represent Ares’ vertically integrated global logistics real estate platform managing facilities that total more than 600 million square feet across the Americas, Europe and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201173799/en/ Marq brings together Ares’ vertically integrated logistics real estate platform in North America and Europe, including Ares Industrial Management, with the global GLP logistics real estate platform outside of China. This follows Ares’ acquisition of the international business and certain affiliates of GLP Capital Partners Limited, which closed in March 2025. With Marq, Ares combines its scale, expertise and integrated logis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom